• EAACI
  • Events
  • Professionals
  • Patients
  • News
Become a Member
Become a Member

Back

Marcus Maurer

Germany

Marcus Maurer

Sessions

Friday 31 May
12:00 - 12:00 Safety of Remibrutinib in Patients With Chronic Spontaneous Urticaria: Results From the Phase 3 REMIX-1 and REMIX-2 Studies
12:00 - 12:00 Adverse Health Outcomes and Patient and Physician Perspectives of Attenuated Androgen Use in Hereditary Angioedema
15:00 - 16:30 Chronic Urticaria: challenges in childhood Symposia Madrid , Channel Madrid
15:00 - 15:30 Chronic inducible urticaria: classification and prominent features of physical and non-physical types
Saturday 1 Jun
08:30 - 08:42 Effect of Remibrutinib on Disease Activity in Patients with Chronic Spontaneous Urticaria: Post Hoc Analysis of Phase 3 REMIX-1 and REMIX-2 studies
08:42 - 08:54 Rilzabrutinib Results in Rapid Improvement of Symptoms in Patients With Chronic Spontaneous Urticaria: Results From the RILECSU Phase 2 Dose-Ranging Study
09:18 - 09:30 Rilzabrutinib Reduces IgG Anti-Thyroid Peroxidase (anti-TPO), Soluble Mas-Related G Protein-Coupled Receptor X2 (sMRGPRX2) and Eosinophils at 12 Weeks in Patients With Chronic Spontaneous Urticaria
09:42 - 09:54 The BEACON Study: A Phase 1b/2a, Dose Escalation Study of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of the c-Kit Mab Briquilimab in Adults with symptomatic Chronic Spontaneous Urticaria (CSU)
12:00 - 12:00 Comparable Efficacy and Pharmacodynamic Results of CT-P39 to Reference Omalizumab in Patients with Chronic Spontaneous Urticaria
12:00 - 12:00 Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)
13:50 - 13:57 Dupilumab Improves Urticaria Activity, Health-Related Quality of Life, and Disease Perception and Severity in Patients with CSU: Results From the LIBERTY-CSU CUPID A Study
Sunday 2 Jun
12:00 - 12:00 SPOTLIGHT: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihis
13:50 - 13:57 Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design
15:12 - 15:24 Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial
×